ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) --
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the second quarter ended June 30, 2025 and provided an overview of the Company’s progress.
Related Questions
How did Oculis's Q2 2025 revenue and earnings compare to consensus estimates and prior quarters?
What guidance or outlook did the company provide for the remainder of 2025, and how might it affect the stock valuation?
Are there any significant pipeline milestones, regulatory approvals, or partnership announcements that could materially impact future cash flows and volatility?